Bio Pharma Dive
SEPTEMBER 6, 2023
Jane Grogan, an industry veteran who worked at Genentech for over 15 years, will take over the role starting Oct. 2. She’ll fill a seat that's lacked a permanent replacement since the departure of Al Sandrock.
Pharmaceutical Technology
SEPTEMBER 5, 2023
Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
SEPTEMBER 5, 2023
The NIH Pragmatic Trials Collaboratory is launching a special Grand Rounds series to share advances in the design and analysis of pragmatic clinical trials. Join us on the first Friday of each month, October through January, to hear the latest best practices and explore emerging questions with experts from the program’s Biostatistics and Study Design Core.
Pharma Mirror
SEPTEMBER 8, 2023
Niclosamide is an anthelmintic medication that has been used for decades to treat various types of parasitic infections in humans and animals. Niclosamide works by disrupting the energy metabolism of the parasitic worms, specifically by interfering with their ability to generate adenosine triphosphate (ATP), which is essential for their survival. This disruption ultimately leads to the death of the parasites.
Bio Pharma Dive
SEPTEMBER 5, 2023
The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.
Pharmaceutical Technology
SEPTEMBER 8, 2023
Eloxx has submitted an IND for a pivotal trial to study its Alport syndrome therapy ELX-02 following a positive Phase II data readout.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Mirror
SEPTEMBER 6, 2023
by Nataliya Andreychuk, Co-founder and CEO of Viseven Many pharma brands still shy away from marketing directly to patients, depending on conversion through healthcare providers (HCPs). And it is not hard to see why. Compliance with complex laws and regulations, like Direct-to-Consumer Advertising (DTCA) Rules or the Health Insurance Portability and Accountability Act (HIPAA), can be quite daunting.
Bio Pharma Dive
SEPTEMBER 8, 2023
Shape uses machine learning and high throughput screening to identify new AAV capsids in ways the company’s CEO compares to the generative AI tools Midjourney and DALLE-2.
Pharmaceutical Technology
SEPTEMBER 7, 2023
Veracyte has announced a partnership with Gustave Roussy to support biopharmaceutical companies in expediting the development
Fierce Pharma
SEPTEMBER 7, 2023
Demand is so strong for Novo Nordisk’s obesity drugs that the only limitation on sales—in the short term—seems to be the company’s ability to produce them. | Promising heart data for Novo Nordisk's Wegovy are a "paradigm shift," according to J.P. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
SEPTEMBER 8, 2023
The company will use its AI technology during a sub-study to analyse the effect of lansoprazole - News - PharmaTimes
Bio Pharma Dive
SEPTEMBER 8, 2023
Worth up to $840 million, the collaboration will give Alexion access to Verge Genomics’ platform, which uses human tissue data to find drug targets for diseases that degrade the nerve system.
Pharmaceutical Technology
SEPTEMBER 8, 2023
In this issue: Digital jobs in UK life sciences, generative AI changes drug discovery, and how robotics is impacting gene therapy manufacturing.
Fierce Pharma
SEPTEMBER 7, 2023
Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. | Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Times
SEPTEMBER 8, 2023
Clinically significant results have emerged from trial evaluating the company’s AMO-02 candidate - News - PharmaTimes
Bio Pharma Dive
SEPTEMBER 8, 2023
The PASTEUR Act could be heading for another legislative blow, but advocates say they see a future for the mechanism to fund research into antimicrobial resistance.
Pharmaceutical Technology
SEPTEMBER 6, 2023
The UK MHRA has granted approval for Pfizer and BioNTech’s adapted Covid-19 vaccine (Comirnaty) targeting the Omicron XBB 1.5 subvariant.
Fierce Pharma
SEPTEMBER 6, 2023
IBM disclosed "unauthorized access" to J&J’s Janssen CarePath patient assistance program, which helped over 1 million U.S. patients last year.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
SEPTEMBER 7, 2023
The treatment targets extensive stage small cell lung cancer and aims to boost therapeutic impact - News - PharmaTimes
Bio Pharma Dive
SEPTEMBER 7, 2023
Fresh off a Series C fundraise, Kriya has acquired the privately held Tramotane Therapeutics and its preclinical candidate for the widely prevalent liver disease.
Pharmaceutical Technology
SEPTEMBER 8, 2023
The European Commission granted expanded indication approval for Merck’s Ebola vaccine, Ervebo, to include children aged one year or above.
pharmaphorum
SEPTEMBER 7, 2023
In today’s episode, sponsored by Veeva, we’ll hear a roundtable discussion on this fascinating topic featuring Victoria Serra Gittermann, European customer experience lead at Veeva Systems and Sebastian Noel, Veeva’s director of multichannel strategy – moderating a discussion with two executives with first-hand experience leading this change: Andy Eeckhout, global head of CRM and digital solutions at Advanz Pharma and Mokhtar Elsayed, head of global go to market commercial transformation at Sano
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
XTalks
SEPTEMBER 6, 2023
This episode features an interview with Dr. David Young, founder and President R&D at Processa Pharmaceuticals, a clinical-stage pharmaceutical company developing personalized approaches to cancer treatments with a focus on next generation chemotherapy drugs with improved safety and efficacy. Processa recently released an update on its clinical cancer program, which Dr.
Bio Pharma Dive
SEPTEMBER 5, 2023
The announcement marks progress for Beam after trial delays, and is the first time in the U.S. that a patient has received a base editing treatment.
Pharmaceutical Technology
SEPTEMBER 8, 2023
The UK NICE has recommended Eli Lilly’s tirzepatide for the treatment of adult patients with inadequately controlled type 2 diabetes.
Pharma Times
SEPTEMBER 6, 2023
Therapy is used among adult patients with symptomatic obstructive hypertrophic cardiomyopathy - News - PharmaTimes
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
XTalks
SEPTEMBER 7, 2023
Los Angeles Lakers and Spain’s basketball legend Pau Gasol is investing in artificial intelligence (AI) company Idoven , which is developing an AI-powered cardiology service platform. The platform is designed to support cardiologists and other clinicians in the identification, triage and diagnosis of patients. The company’s goal is to develop an AI-based cardiology platform that has increased the ability to identify and diagnose cardiovascular diseases on a large scale.
Bio Pharma Dive
SEPTEMBER 5, 2023
The signals of a return to growth are emerging. As commercial leaders gear up for 2024 planning, they must prepare to fight for resources in a budget constrained environment.
Pharmaceutical Technology
SEPTEMBER 7, 2023
The country returns to the EU’s research programme after a Brexit-related absence and questions surrounding its re-entry prospects.
Drug Patent Watch
SEPTEMBER 5, 2023
Pharmacists play a crucial role in drug repurposing due to the vast amount of opportunities that exist in this innovative approach. Drug development and registration can be costly, time-consuming, and… The post Pharmacists Can Play Key Role in Drug Repurposing appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
293 
Let's personalize your content